Details

NameSymbolSector
MEDICAMEN BIOTECH LTD.MEDICAMEQPharmaceuticals
Open
233.9
High
239.4
Low
224
Close
225.25
Volume
42044
Exchange
nse
Time
15-Jun-2026

Outlook

Score:  

3

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Medicamen Biotech is  
None
Estimated Stoploss of Medicamen Biotech is ₹  
239.4
Medicamen Biotech has a  
Bearishℹ
 pattern. 
Formation of  
None
 candle pattern indicates the trend direction of Medicamen Biotech is  
Unpredictableℹ
. 

Trend

Medicamen Biotech is in  
Sideways trendℹ
. 
Price of Medicamen Biotech is  
Downℹ
 by  

13.23

%. 
Target
Buy @ 

219.62

Sell @ 

296.66

Current @ 

225.25

Volume

Medicamen Biotech has seen  
Moderateℹ
 volume of trades. 
The volume trend for Medicamen Biotech is  
Bearishℹ
, but the participants are  
Weak Sellersℹ
The trade volume of Medicamen Biotech is  

Up

 by  

17.88

% 

Valuation

The current market price of Medicamen Biotech is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 297cr and total assets worth ₹ 297cr, the balance sheet of Medicamen Biotech is:  
Balancedℹ
. 
Cashflow
Medicamen Biotech has  
Badℹ
 cash flow because there is  

Shortage

 of  

₹ 11cr

. It is  
Downℹ
 by  

120

%. 

(*Mar 2025)

80% i.e. ₹ 8cr spent in operatingℹ
10% i.e. ₹ 1cr spent in investingℹ
10% i.e. ₹ 1cr spent in financingℹ
0% in otherℹ
Medicamen Biotech has  
Poorℹ
 cash flow because there is  

Shortage

 of  

₹ 5cr

. It is  
Downℹ
 by  

131.25

%. 

(*Mar 2024)

35.29% i.e. ₹ 6cr spent in operatingℹ
29.41% i.e. ₹ 5cr spent in investingℹ
35.29% i.e. ₹ 6cr earned in financingℹ
0% in otherℹ
Income
The income of Medicamen Biotech is  

₹ 47cr

 and  

Profit

 is :  

₹ 2cr

(*Sep 2025)

Medicamen Biotech Profit is up by:  

100

% and Income is Up by:  

9.3

% 

(*Sep 2025)

The income of Medicamen Biotech is  

₹ 43cr

 and  

Profit

 is :  

₹ 1cr

(*Jun 2025)

Medicamen Biotech Profit is up by:  

0

% and Income is Up by:  

26.47

% 

(*Jun 2025)

The income of Medicamen Biotech is  

₹ 34cr

 and  

Profit

 is :  

₹ 1cr

(*Mar 2025)

Medicamen Biotech Profit is down by:  

50

% and Income is Down by:  

24.44

% 

(*Mar 2025)

By using this site you agree to the use of cookies to deliver a better site experience.